Fluzoparib
- Generic Name
- Fluzoparib
- Drug Type
- Small Molecule
- Chemical Formula
- C22H16F4N6O2
- CAS Number
- 1358715-18-0
- Unique Ingredient Identifier
- TWF0ML1CK8
- Background
Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).
- Indication
⑴适用于既往经过二线及以上化疗的伴有胚系BRCA突变(gBRCAm)的铂敏感复发性卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。⑵适用于铂敏感的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在含铂化疗达到完全缓解或部分缓解后的维持治疗。
A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 212
- Registration Number
- NCT05349409
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
- Conditions
- High-risk Prostate CancerNeoadjuvant Therapy
- Interventions
- Drug: Androgen deprivation therapyProcedure: Radical Prostatectomy
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 34
- Registration Number
- NCT05223582
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 490
- Registration Number
- NCT05206890
- Locations
- 🇨🇳
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- The Second Affiliated Hospital of Shandong First Medical University
- Target Recruit Count
- 60
- Registration Number
- NCT05170594
- Locations
- 🇨🇳
The Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong, China
Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05032235
- Locations
- 🇨🇳
The second affiliated hospital of Chongqing medical university, Chongqing, Chongqing, China
Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy
- Conditions
- Nasopharyngeal CarcinomaNasopharyngeal Cancer
- Interventions
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 48
- Registration Number
- NCT04978012
- Locations
- 🇨🇳
Fudan Universtiy Shanghai Cancer Centre, Shanghai, Shanghai, China
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 93
- Registration Number
- NCT04869488
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2021-05-11
- Target Recruit Count
- 65
- Registration Number
- NCT04828395
- Locations
- 🇨🇳
Liu ningbo, Tianjin, China
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT04718740
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04694365
- Locations
- 🇨🇳
Henan Infectious Diseases Hospital, Zhengzhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.